Emerald Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$16.8M Sell
461,402
-54,826
-11% -$1.99M 0.61% 66
2025
Q1
$18.7M Sell
516,228
-2,100
-0.4% -$76K 0.84% 45
2024
Q4
$21.8M Sell
518,328
-51,470
-9% -$2.17M 0.84% 48
2024
Q3
$31.7M Buy
569,798
+83,116
+17% +$4.62M 1.22% 26
2024
Q2
$20M Sell
486,682
-1,456
-0.3% -$59.8K 0.84% 47
2024
Q1
$22.8M Buy
488,138
+6,000
+1% +$280K 0.92% 41
2023
Q4
$23.1M Sell
482,138
-9,551
-2% -$457K 0.99% 37
2023
Q3
$17.5M Sell
491,689
-60,447
-11% -$2.15M 0.85% 48
2023
Q2
$25.5M Buy
552,136
+61,975
+13% +$2.86M 1.11% 29
2023
Q1
$19.7M Buy
490,161
+145,436
+42% +$5.83M 0.94% 41
2022
Q4
$16M Sell
344,725
-2,356
-0.7% -$109K 0.77% 61
2022
Q3
$14.4M Buy
347,081
+145,864
+72% +$6.04M 0.74% 58
2022
Q2
$12M Sell
201,217
-22,735
-10% -$1.36M 0.62% 70
2022
Q1
$16.3M Sell
223,952
-11,793
-5% -$856K 0.62% 68
2021
Q4
$19.8M Buy
235,745
+39,621
+20% +$3.33M 0.73% 60
2021
Q3
$17.7M Sell
196,124
-14,119
-7% -$1.27M 0.64% 67
2021
Q2
$20M Sell
210,243
-18,125
-8% -$1.73M 0.73% 54
2021
Q1
$26M Buy
228,368
+1,493
+0.7% +$170K 0.94% 33
2020
Q4
$31.4M Buy
+226,875
New +$31.4M 1.04% 30
2017
Q1
Sell
-337,629
Closed -$23.7M 262
2016
Q4
$23.7M Buy
337,629
+67,646
+25% +$4.76M 1.01% 35
2016
Q3
$19.2M Buy
+269,983
New +$19.2M 0.85% 30
2015
Q3
Sell
-69,590
Closed -$7.13M 347
2015
Q2
$7.13M Sell
69,590
-1,111
-2% -$114K 0.34% 99
2015
Q1
$4.21M Sell
70,701
-46,480
-40% -$2.77M 0.21% 141
2014
Q4
$5.14M Buy
117,181
+74,480
+174% +$3.27M 0.27% 119
2014
Q3
$2.42M Buy
42,701
+3,991
+10% +$226K 0.14% 190
2014
Q2
$1.74M Buy
38,710
+12,040
+45% +$541K 0.1% 214
2014
Q1
$1.3M Buy
+26,670
New +$1.3M 0.07% 234